Nucleate

Join us for our third Tech Talk with Joel Shor, former VP of Machine Learning at Deep Genomics and now a techbio consultant at Move37 Labs. Discover how his team—working with researchers from MIT and Google—is pushing the boundaries of AI-driven nucleic acid sequence design to engineer superior therapeutics. Wednesday, February 19th, 2pm PST, on zoom. Register: https://lnkd.in/gzWivg2A About the series: Nucleate’s AIxBio Tech Talks provide real world insight into how AI is transforming biotech. In each session, attendees will hear from a leading practitioner in AIxBio about their vision and technical approach, followed by an audience Q&A.

Today’s the day! Junevity today is officially announcing our first $10 million of Seed VC funding to develop cell reset therapeutics for longevity. We’re on a mission to extend lifespan and healthspan by resetting cell damage from age-related diseases. Founded out of UCSF in 2023, Junevity’s RESET platform is the first to use large-scale human data and AI to identify novel transcription factor targets and repress them with siRNA. The initial focus is Type 2 diabetes, obesity and frailty, with the potential to address numerous longevity and aging-related indications. We thank Adam Ross and Daniel Friedland at Goldcrest Capital and Jason Godfrey at Godfrey Capital for their lead investment, support and partnership. Read more about our funding here: https://lnkd.in/gJbJWU5U Coverage by Longevity.Technology: https://lnkd.in/eJgnUwuD Coverage by Endpoints News: https://lnkd.in/g_rqbXpM

Junevity Raises $10M to Develop Cell Reset Therapeutics for Longevity! Founded by a team of experts in aging biology, machine learning and drug development and based on pioneering research for resetting cell health by Dr. Janine Sengstack of UCSF. Junevity’s RESET platform uses large-scale human data and AI to identify novel transcription factor targets and repress them with siRNA. The initial focus is Type 2 diabetes, obesity and frailty, with the potential to address numerous indications. Congratulations to Dr. Janine Sengstack (the one in the middle), the UCSF founder. Read: https://lnkd.in/gJbJWU5U

Join Us for the Second Inside Fundraising Seminar – Exploring Alternatives to Venture Capital! Looking for funding beyond traditional venture capital? Discover the potential of philanthropic and angel investing in the next session of our Inside Fundraising Series. We’re featuring two experienced investors who will share their insights: ▫️ Lili Clark, Senior Associate at Lyda Hill Philanthropies/Lyda Hill Capital Inc. ▫️ Zack Storms, Co-founder at TNT Startups They’ll discuss their companies’ current investment criteria, how to connect with them, and best practices for communicating with these funding sources. Don’t miss this chance to explore alternative funding opportunities and gain expert insights! Register here: https://lu.ma/qzqjyxlu

Join us for a pivotal conversation on the future of aging therapeutics! On March 3, 2025, we’re continuing Nucleate: Inside Aging with an insightful virtual session featuring leaders in aging biology and therapeutics: 🎙 Nir Barzilai, MD Founder and Director, Institute for Aging Research 🎙 Joan Mannick, MD CEO & Co-Founder, Tornado Therapeutics 🎙 Matt Kaeberlein, Ph.D. CEO, Optispan, Inc. These renowned experts will share their vision on the path from aging therapeutics research to clinical applications and how you can get involved in the field’s groundbreaking work. This is a must-attend event for: ▫️ Researchers and students passionate about aging therapeutics. ▫️ Investors exploring innovative aging biotech. ▫️Anyone eager to understand how science is transforming aging and health. 💡 Don’t miss out—register today: https://lnkd.in/gbfend-E 💡 1pm ET Let’s innovate and shape the future of aging therapeutics together! #AgingTherapeutics #AgingBiology #Longevity #NucleateInsideAging #Innovation #Biotechnology #VirtualEvent

Join us this Wednesday, February 12th, for the Next Inside Business Development Seminar! This seminar will focus on developing your commercialization strategy and the key factors to consider during the early-stage company formation process. We’re excited to feature two accomplished entrepreneurs: ▫️ Erwin Estigarribia, CEO of Headlamp Health ▫️ Celina Burns, Co-founder & CEO of Unifyed Health They’ll share firsthand insights on successfully launching and scaling companies in a moderated Q&A, followed by an open floor discussion where you can ask your burning questions. Don't miss this opportunity to learn from industry leaders and connect with like-minded professionals! RSVP here: https://lu.ma/5cd9xlsi

🚀 Revolutionizing Gene Therapy with AI-Powered Capsid Engineering What happens when you combine physics, systems biology, and machine learning to tackle one of the biggest challenges in gene therapy? You get Dyno Therapeutics—a company pioneering AI-driven capsid engineering to improve gene delivery and make therapies more effective and accessible. In this latest episode with Sam Kessel MD, MBA, Eric Kelsic, CEO and co-founder of Dyno, shares his journey: 🔬 How his physics and systems biology background shaped his approach to solving biological problems 🧬 Lessons learned from working in George Church’s lab at Harvard 🤖 How Dyno uses machine learning to engineer better AAV capsids 🤝 Using the scientific method to approach business development Kelsic’s story is a masterclass in identifying high-impact problems, leveraging cutting-edge technology, and translating scientific insights into therapeutics to improve patient’s lives. Check out the full episode to dive into the future of AI-powered gene therapy! 🎧👇 https://lnkd.in/gt6TDTZY #GeneTherapy #AI #Biotech #Innovation #MachineLearning

Are you a biotech founder looking to fast-track your clinical development? Australia offers a streamlined regulatory framework, generous R&D tax incentives, and world-class trial execution strategies—making it a prime hub for biotech innovation. Join Nucleate Australia for an exclusive virtual panel featuring industry leaders who will share key insights into why Australia is the ideal destination for your next clinical trial. Speakers: Michelle Gallaher– CEO of Cerulea and a seasoned expert in the Australian clinical trials landscape, offering unparalleled insights into trial execution and local opportunities. Professor Lauren Ayton AM– Associate Dean of Innovation and Enterprise, and an expert in ophthalmological trials, medtech, and regulatory affairs. Dr. Philip Ryan- Nucleus Network Director, Medical group leader at the Florey Institute of Neuroscience. Dr. Daniel G.– Australian Founder and CEO of Myeloid Therapeutics. Daniel brings a wealth of first-hand experience, having established his biotech company in Boston while conducting successful clinical trials in Australia. CSL Representative– From Australia’s largest biotech company, providing a global perspective on Australia’s standing in clinical trials. Date & Time: February 6th – 9:00 AM AEDT (Melbourne) February 5th – 5:00 PM EST (Boston) 📍 Location: Virtual – Register here: https://lu.ma/uvw8ddvp #Biotech #ClinicalTrials #Innovation #LifeSciences #Entrepreneurship

Nucleate is proud to announce a new addition to our global family: Nucleate Netherlands , as an Associate Chapter! “We are very excited to welcome the Netherlands Chapter to the global family. We’ve been working closely with the local team and are excited to see their impact on the ecosystem.” said Onkar Date, EVP Global Strategy at Nucleate. The Netherlands is a hub of biotech and life sciences innovation, supported by excellent universities, research centers, and a welcoming environment for international talent. With its strong governmental backing for life sciences and agri-food as top sectors, companies and innovators can benefit from tax incentives, innovation credits, and grants, with recent initiatives supporting the commercialization of early-stage discoveries. Beyond public support, the Netherlands is also home to some of Europe’s largest biotech investors, and Dutch biotech startups secured well over $600 million in VC funding in 2024. However, “Challenges remain, including a fragmented ecosystem, insufficient scale-up funding, a limited entrepreneurial mindset among academic trainees, and a shortage of talent with commercial expertise”, says Samuel Feldmann, Director of Partnerships. Nucleate Netherlands is uniquely positioned to address these gaps by fostering collaboration across the ecosystem. Through partnerships with local initiatives and tailored programming for academic and young founders, we aim to bridge fragmented hubs and nurture a thriving entrepreneurial culture. By leveraging Nucleate’s global network and local expertise, we’re excited to support the next generation of biotech leaders in realizing their potential. Central to this effort are co-Managing Directors Elena Del Pup and Martin Holub, Director of Partnerships Samuel Feldmann along with the strong founding team that has worked on bringing Nucleate to the region over the last year. Stay tuned as we work towards empowering innovation in the Dutch biotech ecosystem!

We are thrilled to welcome 18 exceptional venture teams into our 2025 Nucleate Global Virtual Activator cohort—our largest and most geographically diverse yet! 🌐 This year’s cohort brings together 55 individuals from 41 cities, 25 countries, and 5 continents. These biotech pioneers—many starting as students/trainees—are harnessing innovation to tackle pressing challenges in human and planetary health. 🌍 🌎 🌏 Spanning 20 time zones (from Los Angeles to Melbourne), our teams are building exciting solutions across Therapeutics, ClimateTech, TechBio, Diagnostics, MedTech, and more—a vast range of challenges. Yet, what unites them is a shared vision: that biotechnology holds the key to solving the world’s greatest challenges. 💡 Want to meet these founders? Passionate about empowering the next generation of biotech leaders? 📢 We are seeking operators, founders, investors, industry scientists, entrepreneurial academics, and all other bio-professionals to join us on this journey. Get involved as: - Mentor: provide deep, sustained guidance to a venture team (1 hr/2 wks) - Expert: share strategic insights at virtual workshops on key tenets of life science venture creation (2 hrs/workshop) - Sponsor: forge tailored financial partnerships to align missions and fuel biotech innovation Mentorship/Expert Program: mentor.nucleate.org Sponsorship: global@nucleate.org or DM me! 🤝 Let's work together to catalyze biotech innovation on a global scale. Regan Ellis Madison Lenormand Eva Smorodina Vivian Chiu Cindy Lu Clara Brouaux Kenza Mourji Alexander Anisimov Kevin Antonio Cahya Samantha Fabregat Min Joo Kim Emma Osswald Anthony A. Richard Dela Rosa Samuel Feldmann Megan Tsao Justus Florian Gräf Suyen Espinoza Miranda, PhD Fariha Reza Julia Nanyi Zhao, PhD Heer Joisher Zach Cogan Soufiane Aboulhouda, PhD Oliver Dodd